Guest: Thomas Caulfield, Ph.D.

Host: Amit K Ghosh, M.D., MBA (@AmitGhosh006)

In this podcast, Dr. Thomas Caulfield from Mayo Clinic Florida describes a novel approach for SARS-CoV2 multi-drug targeting using artificial intelligence. Dr. Caulfield is leading a national team of investigators from Harvard, University of California, In Vivo Biosystems and Mayo Clinic to perform large-scale in silico and in vivo experiments on de novo drugs to better understand COVID-19 and halt its progression.  University of California hosts a live virus BSL3 facility for rapidly screening novel compounds that Dr. Caulfield’s lab designs in silico and refines with feedback using machine learning techniques and data layering.

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.